Saldia A, et al. - Given that the risk for pancreatic ductal adenocarcinoma (PDAC) is greater with germline mutations in BRCA1/2, researchers performed this prospective study within the Pancreatic Tumor Registry at a major cancer center to assess if outcomes after surveillance for PDAC in high-risk individuals (HRI) vary between those with vs without a pathogenic BRCA1/2 mutation. Surveillance and testing for pathogenic germline mutations in BRCA1/2 was conducted in 83 HRI with >=1 first degree relative with PDAC. Irrespective of BRCA1/2 mutation status, comparable imaging results for pancreatic abnormalities surveillance were seen. Findings revealed that targeting subjects with BRCA1/2 mutations for surveillance did not seem to increase the yield currently.